Effect of Dihydrocapsiate on Energy Expenditure in Women
NCT ID: NCT01773356
Last Updated: 2015-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
126 participants
INTERVENTIONAL
2011-01-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate
NCT00999297
Breakfast and Energy Expenditure in Young Women
NCT03079635
Variations in Ketone Metabolism
NCT05924295
Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism
NCT03878108
Very Low Ketogenic Diet and Energy Expenditure
NCT06252077
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo 0 mg/d
0 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
Dihydrocapsiate
Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
Dihydrocapsiate 9 mg/d
9 mg/d of Dihydrocapsiate will be consumed in ready to ear cereal, cereal bars or crackers
Dihydrocapsiate
Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dihydrocapsiate
Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good general health
* Low to mild physical activity
* Willing to maintain habitual diet and physical activity patterns throughout the study period
* Premenopausal and cycling regularly or using oral contraceptives
* Willing to attend study visits only during the follicular phase or bleed phase of their menstrual cycle
* Understands study procedures and signs forms providing informed consent to participate in the study
* Have spoken and written English literacy
Exclusion Criteria
* Weight change ±2 kg over previous three months
* Known sensitivity or allergy to ingredients of the study products
* Non-breakfast eater
* Recent use of antibiotics
* History of smoking during the six months prior to study
* Recent signs or symptoms of infection, including cold or flu-like symptoms
* Concurrent or recent intervention study participation
* Instability in breathing patterns or energy expenditure measures
* History of drug or alcohol abuse
* Lipid-lowering, anti-hypertensive or anti-inflammatory steroid medication use
* Weight loss medication
* Pregnant or lactating
* Unwilling to be randomized to any experimental group and unable to meet all requirements of the study
25 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kellogg Company
INDUSTRY
Ellen Evans
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ellen Evans
Dr Ellen Evans
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ellen M Evans, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Georgia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Georgia, Department of Kinesiology
Athens, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WASABI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.